Ravi Viswanathan's Net Worth

$364 Million

Who is Ravi Viswanathan?

Ravi Viswanathan has an estimated net worth of $364 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., Cascadian Therapeutics, Inc., Workday, Inc., Care.com Inc, Millennial Media Inc., AEROHIVE NETWORKS, INC, MULESOFT, INC, Elastic N.V., AVEO PHARMACEUTICALS INC, APPIAN CORP, Mersana Therapeutics, Inc., Clovis Oncology, Inc., Adaptimmune Therapeutics PLC, Duolingo, Inc., BOX INC, Loxo Oncology, Inc., Dermira, Inc., CHAMPIONS ONCOLOGY, INC., Surface Oncology, Inc., GENOCEA BIOSCIENCES, INC., PhaseBio Pharmaceuticals Inc, TESARO, Inc., ARDELYX, INC., GLYCOMIMETICS INC, Tracon Pharmaceuticals, Inc., SYNLOGIC, INC., Epizyme, Inc., Arsanis, Inc., Cerecor Inc., Roka BioScience, Inc., Regulus Therapeutics Inc., ARCA biopharma, Inc., Marker Therapeutics, Inc., Omthera Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Strongbridge Biopharma plc, CVENT INC, Achaogen Inc, and INTERLEUKIN GENETICS INC.

SEC CIK

Ravi Viswanathan's CIK is 0001479386

Past Insider Trading and Trends

2018 was Ravi Viswanathan's most active year for acquiring shares with 59 total transactions. Ravi Viswanathan's most active month to acquire stocks was the month of February. 2014 was Ravi Viswanathan's most active year for disposing of shares, totalling 24 transactions. Ravi Viswanathan's most active month to dispose stocks was the month of September. 2016 saw Ravi Viswanathan paying a total of $94,738,980.53 for 55,383,077 shares, this is the most they've acquired in one year. In 2017 Ravi Viswanathan cashed out on 82,295,400 shares for a total of $66,073,750.64, their largest year based on trade value.